A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD

Running, not enrolling

Conditions studied: Autosomal Dominant Polycystic Kidney Disease

In brief

The purpose of this study is to assess homocysteine metabolism and systemic endothelial function at the early stages of the disease and determine the prognostic value of homocysteine, related metabolites, and markers of endothelial function and injury to estimate renal disease severity and progression in patients with early Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Key facts

Study ID

NCT05193981

Run by

Mayo Clinic

People needed

80

Starts

2021-09-14

Expected to finish

2026-12-01

Last updated by the study team

2026-04-16

Who can join

Age: 15 and older, up to 40. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and Female subjects, 15-40 years of age, inclusive
• Previous diagnosis of ADPKD (Based on Ravine et al. criteria)
• Class 1 according to imaging classification
• Estimated GFR>70 mL/min/1.73m\^2(CKD-EPI)
• Ability to provide written, informed consent.

You may not qualify if…

• Class 2 according to imaging classification
• A concomitant systemic disease affecting the kidney
• Diabetes mellitus
• Predicted urine protein excretion in urinalysis >1 g/24 hrs
• Subjects having contraindications to or interference with MRI assessments
• Patients that are part of an interventional study or taking tolvaptan
• Female subjects that are pregnant

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.